How Cagrilintide Storage and Stability Are Described in the Research

What the published record actually covers

Cagrilintide is a long-acting amylin analogue that has been studied in obesity and type 2 diabetes programmes, frequently in combination with a GLP-1 receptor agonist; a 2026 Endocrine Reviews overview of novel GLP-1-based medications for type 2 diabetes and obesity discussed amylin-based agents among the newer pharmacological approaches under investigation (https://pubmed.ncbi.nlm.nih.gov/41054801/). Because the compound sits in the prescription-medicine pathway rather than on an open shelf, there is no publicly circulated patient storage leaflet of the kind that accompanies a marketed product, and sponsor-controlled trial supply is handled under protocol-specific pharmacy instructions that are not published as stability literature.

That leaves two separate bodies of information, and this page keeps them separate throughout. The first is cagrilintide-specific science: structural characterisation of how the peptide engages its receptors, and in vitro work on how it is metabolised. The second is general lyophilized-peptide and solution-peptide stability science, which describes how peptides as a chemical class behave with temperature, water, light, agitation and time. Where a statement below rests on the second body of knowledge rather than on cagrilintide data, it is flagged as general formulation science.

This page is for educational purposes only and is not medical advice; consult a licensed physician or pharmacist about any question involving a prescribed or investigational medicine, including how a specific supply should be kept.

Regulatory framing first

Storage rules for medicines are normally set by a regulator-approved product label, not by independent researchers. For an agent still moving through clinical development, the controlling documents are the investigator's brochure and the pharmacy manual for each trial site. The 2026 Endocrine Reviews article placed amylin analogue development within the broader landscape of newer agents for type 2 diabetes and obesity (https://pubmed.ncbi.nlm.nih.gov/41054801/), but reviews of that kind describe clinical evidence, not container-closure or cold-chain specifications. Nothing on this page substitutes for the handling instructions attached to a dispensed product by the clinician or pharmacist responsible for it.

Refrigeration: lyophilized versus reconstituted

General peptide formulation science draws a sharp line between a freeze-dried (lyophilized) powder and the same peptide once it is in aqueous solution. In the dried state, the water activity that drives hydrolysis, deamidation and many aggregation pathways is largely removed, so dried peptide preparations are conventionally the more thermally forgiving of the two. Once water is reintroduced, the molecule becomes mobile, chemical degradation routes reopen, and the practical stability window shortens considerably. Marketed injectable peptide and protein products are commonly distributed in a 2-8 °C cold chain for this reason, which is a general pharmaceutical convention rather than a published cagrilintide finding.

No peer-reviewed study in the verified literature set reports a shelf-life figure, a reconstituted hold time, or an excursion tolerance for cagrilintide. Any specific number attached to this compound online that is not traceable to a regulator-approved label or a sponsor document should be treated as unsourced.

Why amylin analogues are an aggregation-sensitive class

Amylin itself is a famously aggregation-prone peptide, and analogue design in this family has had to engineer around that tendency. A 2022 study in Colloids and Surfaces B: Biointerfaces examined the amyloidogenicity of peptides developed as therapies for diabetes and obesity and characterised how sequence and physicochemical conditions relate to fibril-forming behaviour in this therapeutic class (https://pubmed.ncbi.nlm.nih.gov/34715595/). Researchers in that work reported on the self-assembly behaviour of peptides in this space rather than on commercial storage conditions, so the relevance here is conceptual: aggregation is a recognised failure mode for amylin-derived molecules, and the conditions that classically accelerate peptide aggregation in general formulation science are heat, repeated freeze-thaw cycling, air-liquid interface exposure from shaking, and extremes of pH or concentration.

Structure, conformation and why integrity matters

Storage discussions ultimately concern whether a molecule still has the shape and sequence that produce receptor engagement. A 2026 study in Acta Pharmacologica Sinica reported structural and mechanistic insights into how cagrilintide activates both amylin and calcitonin receptors, describing the molecular basis of its dual receptor activity (https://pubmed.ncbi.nlm.nih.gov/40847076/). The study did not test storage conditions. Its relevance to a stability page is that receptor activation in this family is conformation-dependent, which is the underlying reason formulation scientists treat aggregation and covalent modification as potency-relevant events rather than cosmetic ones.

Degradation chemistry: What Studies Report

Chemical breakdown of a peptide drug happens by two broad routes, chemical degradation in the vial and enzymatic degradation in the body, and only the second has cagrilintide-specific published data in this set. A 2026 paper in the Journal of Pharmaceutical and Biomedical Analysis reported in vitro metabolic profiling of weight-loss-inducing amylin receptor agonists in a preventive doping-research context, characterising the metabolite patterns these peptides generate in vitro (https://pubmed.ncbi.nlm.nih.gov/41702251/). That work describes enzymatic processing in biological matrices, not vial stability, and the two should not be conflated, an in vitro metabolite profile says nothing about how a sealed container behaves on a shelf.

On the formulation side, general peptide chemistry describes the recurring in-vial degradation routes as follows, none of which are cagrilintide-specific findings:

• Hydrolysis, backbone cleavage accelerated by water and heat, which is why dried formats are conventionally handled differently from solutions.
• Deamidation, conversion at asparagine and glutamine residues, pH- and temperature-sensitive.
• Oxidation, affecting methionine, cysteine and tryptophan residues, promoted by light, oxygen and trace metals.
• Aggregation and fibrillation, self-association into soluble oligomers or insoluble fibrils, the pathway that the 2022 amyloidogenicity study characterised for peptides in the diabetes and obesity space (https://pubmed.ncbi.nlm.nih.gov/34715595/).
• Adsorption, loss of material onto container and device surfaces, usually countered by excipients in a finished product.

Freezing, freeze-thaw and temperature excursions

General protein and peptide formulation science treats freezing as a mixed intervention: very low temperatures slow chemical reactions, but the freezing and thawing transitions themselves create ice-water interfaces, local concentration spikes and pH shifts in buffered systems, all of which are classical aggregation triggers. Repeated cycling is described in that general literature as more damaging than a single transition. There is no published freeze-thaw dataset for cagrilintide in the verified literature, so no claim can be made about how this particular molecule and its formulation respond. Where a finished medicinal product exists, excursion handling is a labelled property of that product and a question for the dispensing pharmacy.

Room temperature, light and travel

Ambient storage and transport questions are, for prescription medicines, answered by the product label and by the pharmacy that supplied the item, including whether an in-use period at room temperature is permitted and for how long. Independent stability literature for cagrilintide does not provide those numbers. General peptide science notes that elevated temperature accelerates essentially every degradation route listed above, that ultraviolet and visible light exposure contributes to oxidative damage in susceptible residues, and that mechanical agitation during transport increases air-liquid interface exposure, which the broader aggregation literature associates with nucleation of peptide self-assembly, consistent with the aggregation-prone character described for this therapeutic class (https://pubmed.ncbi.nlm.nih.gov/34715595/).

Evidence map: what is compound-specific and what is not

Visible signs that formulation scientists associate with degradation

In general pharmaceutical quality terms, the visual cues that prompt a product to be withdrawn from use are cloudiness or haze in what should be a clear solution, visible particulates or flocculation, colour change, a cake in a lyophilized vial that has collapsed, melted or shrunk, and leakage or loss of vial integrity. These are generic inspection criteria used across injectable products, not cagrilintide trial findings, and a clear-looking solution is not evidence of chemical integrity, the aggregation literature for peptides in the diabetes and obesity space described self-assembly processes that begin well before anything is visible (https://pubmed.ncbi.nlm.nih.gov/34715595/). Any concern about the appearance of a dispensed medicine is a question for the pharmacist or clinician who supplied it.

Where this leaves the storage question

The honest summary is that cagrilintide's published literature to date is about mechanism, receptor pharmacology, metabolism and clinical development rather than about shelf conditions: structural work described its dual receptor activation (https://pubmed.ncbi.nlm.nih.gov/40847076/), in vitro work characterised its metabolite profile (https://pubmed.ncbi.nlm.nih.gov/41702251/), and a 2026 review situated amylin-based agents within newer obesity and type 2 diabetes pharmacotherapy (https://pubmed.ncbi.nlm.nih.gov/41054801/). Storage specifics for a prescription or investigational medicine come from its label and its dispensing pharmacy, and every use question belongs with a prescribing clinician.

For the general chemistry behind temperature, moisture, light and freeze-thaw effects across peptides as a class, see how peptides are stored and why. For background on cagrilintide's mechanism and trial evidence, see the cagrilintide overview.

References

• Novel GLP-1-based Medications for Type 2 Diabetes and Obesity (Endocrine Reviews, 2026)
• Amyloidogenicity of peptides targeting diabetes and obesity (Colloids and Surfaces B: Biointerfaces, 2022)
• Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors (Acta Pharmacologica Sinica, 2026)
• In vitro metabolic profiling of weight-loss-inducing amylin receptor agonists in the context of preventive doping research (Journal of Pharmaceutical and Biomedical Analysis, 2026)